[Oramed] has spent a total of just $12 million in cumulative R&D since 2002[!]. Novo Nordisk spent $635 million on R&D in the fourth quarter of 2013 alone.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”